Literature DB >> 29210308

Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.

Carlotta Friedmann1, Pierre Levy2, Paul Hensel1, Mickaël Hiligsmann1.   

Abstract

INTRODUCTION: Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs. AREAS COVERED: We provide an overview of the existing evidence regarding the use of MCDA in the appraisal of orphan drugs worldwide. Three databases (Pubmed, Embase, Web of Science) were searched for English, French and German literature published between January 2000 and April 2017. Full-text articles were supplemented with conference abstracts. A total of seven articles and six abstracts were identified. EXPERT COMMENTARY: The literature suggests that MCDA is increasingly being used in the context of appraising orphan drugs. It has shown itself to be a flexible approach with the potential to assist in decision-making regarding reimbursement for orphan drugs. However, further research regarding its application must be conducted.

Entities:  

Keywords:  MCDA; Multi-criteria decision analysis; appraisal; orphan drugs; rare diseases; reimbursement; systematic review

Mesh：

Year:  2017        PMID： 29210308     DOI： 10.1080/14737167.2018.1414603

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


  7 in total

Review 1.  Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries.

Authors:  Yitong Wang; Tingting Qiu; Junwen Zhou; Clément Francois; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01-11       Impact factor: 2.561

Review 2.  Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making.

Authors:  J M Stratil; R Baltussen; I Scheel; A Nacken; E A Rehfuess
Journal:  Cost Eff Resour Alloc       Date:  2020-02-11

Review 3.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

4.  Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.

Authors:  Carina Schey; Maarten Jacobus Postma; Paul F M Krabbe; Olekdandr Topachevskyi; Andrew Volovyk; Mark Connolly
Journal:  Front Public Health       Date:  2020-05-08

5.  Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).

Authors:  Laura Guarga; Xavier Badia; Mercè Obach; Manel Fontanet; Alba Prat; Atonio Vallano; Josep Torrent; Caridad Pontes
Journal:  Orphanet J Rare Dis       Date:  2019-06-27       Impact factor: 4.123

6.  Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.

Authors:  Tamás Zelei; Nicholas D Mendola; Baher Elezbawy; Bertalan Németh; Jonathan D Campbell
Journal:  Pharmacoecon Open       Date:  2021-05-18

7.  Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?

Authors:  Aleksandra Baran-Kooiker; Marcin Czech; Coen Kooiker
Journal:  Front Public Health       Date:  2018-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.